These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 10354174)
21. Chemical structure of urinary dermatan sulfate excreted by a patient with the Hunter syndrome. Kimura A; Hayashi S; Tsurumi K Tohoku J Exp Med; 1980 Jul; 131(3):241-7. PubMed ID: 6774445 [TBL] [Abstract][Full Text] [Related]
22. Early response to idursulfase treatment in a 3 year-old boy affected of Hunter syndrome. Galán-Gómez E; Guerrero-Rico A; Cáceres-Marzal C; Zambrano-Castaño M; Moreno-Tejero ML; Grande-Tejada AM; Fernández-Hernández S; Vaquerizo-Madrid J; Cardesa-García JJ Eur J Med Genet; 2008; 51(3):268-71. PubMed ID: 18396123 [TBL] [Abstract][Full Text] [Related]
23. [Postnatal and prenatal diagnosis of mucopolysaccharidosis type II (Hunter syndrome)]. Zhang WM; Shi HP; Li BT; Zhao SM; Qi QW; Sun NH; Huang SZ Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):644-7. PubMed ID: 17217652 [TBL] [Abstract][Full Text] [Related]
25. First experience of enzyme replacement therapy with idursulfase in Spanish patients with Hunter syndrome under 5 years of age: case observations from the Hunter Outcome Survey (HOS). Alcalde-Martín C; Muro-Tudelilla JM; Cancho-Candela R; Gutiérrez-Solana LG; Pintos-Morell G; Martí-Herrero M; Munguira-Aguado P; Galán-Gómez E Eur J Med Genet; 2010; 53(6):371-7. PubMed ID: 20709629 [TBL] [Abstract][Full Text] [Related]
26. Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future. Whiteman DA; Kimura A Drug Des Devel Ther; 2017; 11():2467-2480. PubMed ID: 28860717 [TBL] [Abstract][Full Text] [Related]
27. Mutation analysis of iduronate-2-sulphatase gene in 24 patients with Hunter syndrome: characterisation of 6 novel mutations. Mutation in brief no. 249. Online. Hartog C; Fryer A; Upadhyaya M Hum Mutat; 1999; 14(1):87. PubMed ID: 10447264 [TBL] [Abstract][Full Text] [Related]
28. Administration of iduronate sulfatase by plasma exchange to patients with the Hunter syndrome: a clinical study. Brown FR; Hall CW; Neufeld EF; Munoz LL; Braine H; Andrzejewski S; Camargo EE; Mark SA; Richard JM; Moser HW Am J Med Genet; 1982 Nov; 13(3):309-18. PubMed ID: 6817638 [TBL] [Abstract][Full Text] [Related]
29. A straightforward, quantitative ultra-performance liquid chromatography-tandem mass spectrometric method for heparan sulfate, dermatan sulfate and chondroitin sulfate in urine: an improved clinical screening test for the mucopolysaccharidoses. Zhang H; Wood T; Young SP; Millington DS Mol Genet Metab; 2015 Feb; 114(2):123-8. PubMed ID: 25458519 [TBL] [Abstract][Full Text] [Related]
30. Heterozygote detection in Hunter syndrome. Zlotogora J; Bach G Am J Med Genet; 1984 Mar; 17(3):661-5. PubMed ID: 6424473 [TBL] [Abstract][Full Text] [Related]
31. Hunter syndrome presenting as macrocephaly and hydrocephalus. Yatziv S; Epstein CJ J Med Genet; 1977 Dec; 14(6):445-7. PubMed ID: 146740 [TBL] [Abstract][Full Text] [Related]
32. A new polymorphism in the iduronate-2-sulphatase gene. Implications for the diagnosis of Hunter disease. Gort L; Chabás A; Coll MJ J Inherit Metab Dis; 1999 Oct; 22(7):844. PubMed ID: 10518288 [No Abstract] [Full Text] [Related]
33. Gene diagnosis and carrier detection in Hunter syndrome by the iduronate-2-sulphatase cDNA probe. Gal A; Beck M; Sewell AC; Morris CP; Schwinger E; Hopwood JJ J Inherit Metab Dis; 1992; 15(3):342-6. PubMed ID: 1357230 [No Abstract] [Full Text] [Related]
34. A novel fluorometric enzyme analysis method for Hunter syndrome using dried blood spots. Tolun AA; Graham C; Shi Q; Sista RS; Wang T; Eckhardt AE; Pamula VK; Millington DS; Bali DS Mol Genet Metab; 2012 Mar; 105(3):519-21. PubMed ID: 22227323 [TBL] [Abstract][Full Text] [Related]
35. Frequent deletions at Xq28 indicate genetic heterogeneity in Hunter syndrome. Wilson PJ; Suthers GK; Callen DF; Baker E; Nelson PV; Cooper A; Wraith JE; Sutherland GR; Morris CP; Hopwood JJ Hum Genet; 1991 Mar; 86(5):505-8. PubMed ID: 1901826 [TBL] [Abstract][Full Text] [Related]
36. Mucopolysaccharidosis type II (Hunter syndrome): characterization of the iduronate-2-sulphatase in MPS II skin fibroblasts. Petruschka L; Zschiesche M; Bielicki J; Seidlitz G; Machill G; Hopwood JJ; Herrmann FH J Inherit Metab Dis; 1994; 17(1):89-92. PubMed ID: 8051941 [No Abstract] [Full Text] [Related]
37. Mucopolysaccharidosis type II with inguinal hernia. Rayamajhi A; Pokharel PJ; Chapagain R; Rayamajhi AK J Nepal Health Res Counc; 2013 Sep; 11(25):293-5. PubMed ID: 24908534 [TBL] [Abstract][Full Text] [Related]
38. Prevalence and characterization of cardiac involvement in Hunter syndrome. Kampmann C; Beck M; Morin I; Loehr JP J Pediatr; 2011 Aug; 159(2):327-31.e2. PubMed ID: 21529823 [TBL] [Abstract][Full Text] [Related]
39. Separation of dermatan sulfate from heparan sulfate in mucopolysaccharidosis urine by chromatography on Sephadex G-75. Herd JK; Forrest T; Tschida J Clin Chim Acta; 1976 Apr; 68(1):1-9. PubMed ID: 131009 [TBL] [Abstract][Full Text] [Related]
40. Evaluation of cerebrospinal fluid heparan sulfate as a biomarker of neuropathology in a murine model of mucopolysaccharidosis type II using high-sensitivity LC/MS/MS. Tanaka N; Kida S; Kinoshita M; Morimoto H; Shibasaki T; Tachibana K; Yamamoto R Mol Genet Metab; 2018 Sep; 125(1-2):53-58. PubMed ID: 30064964 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]